Compare LMAT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | AGIO |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2006 | 2013 |
| Metric | LMAT | AGIO |
|---|---|---|
| Price | $94.30 | $36.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $105.80 | $38.88 |
| AVG Volume (30 Days) | 292.9K | ★ 1.0M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $249,602,000.00 | $43,011,000.00 |
| Revenue This Year | $14.21 | $76.75 |
| Revenue Next Year | $8.88 | $170.73 |
| P/E Ratio | $138.13 | ★ N/A |
| Revenue Growth | ★ 13.53 | N/A |
| 52 Week Low | $79.01 | $22.24 |
| 52 Week High | $118.01 | $46.00 |
| Indicator | LMAT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 76.71 |
| Support Level | $82.26 | $36.43 |
| Resistance Level | $97.83 | $43.72 |
| Average True Range (ATR) | 3.02 | 1.48 |
| MACD | 0.63 | 0.74 |
| Stochastic Oscillator | 61.26 | 95.39 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.